HIKALNSEHikal Limited· PharmaceuticalsLowNeutral
Announced Tue, 23 Sept · 19:05 IST

Hikal Limited has informed the Exchange regarding Summary of proceedings alongwith the Scrutinizers Report on Evoting at the 37th Annual General Meeting held on September 23, 2025

Board & Shareholder Meetings View source PDF

HIKAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Hikal Limited held its 37th Annual General Meeting on September 23, 2025, at 11:30 AM via video conferencing, with 80 members attending. Five ordinary resolutions were put to vote and all were passed with overwhelming majority (over 99% in favor). Key items included adoption of FY25 audited financial statements (99.48% in favor) and confirmation of a total dividend of ₹1.40 per equity share (₹0.60 interim + ₹0.80 final) for FY 2024-25, which received 99.88% support. Other resolutions covered the reappointment of Mr. Amit Kalyani as Non-Executive Director, appointment of M/s. Dhrumil M. Shah & Co. LLP as Secretarial Auditors for a five-year term (FY 2025-26 to FY 2029-30), and ratification of remuneration for the Cost Auditors. The Chairman highlighted the company's focus on entering the niche speciality chemicals segment with strong growth potential.

Likely market impact

All resolutions cleared with near-unanimous shareholder approval, signalling strong investor confidence. The confirmed ₹1.40 per share total dividend for FY25 is positive for income-focused shareholders, while the renewed emphasis on speciality chemicals indicates the company's growth strategy direction.